OTCMKTS:PMCUF Pro Medicus (PMCUF) Stock Price, News & Analysis $194.00 -8.85 (-4.36%) As of 12:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Pro Medicus Stock (OTCMKTS:PMCUF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pro Medicus alerts:Sign Up Key Stats Today's Range$194.00▼$202.9650-Day Range$169.99▼$218.2552-Week Range$96.44▼$218.25Volume245 shsAverage Volume798 shsMarket CapitalizationN/AP/E Ratio12,933.33Dividend Yield0.01%Price TargetN/AConsensus RatingN/A Company Overview Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia. Read More Pro Medicus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScorePMCUF MarketRank™: Pro Medicus scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pro Medicus. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro Medicus is 12,933.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro Medicus is 12,933.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.16.Read more about Pro Medicus' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 366.6, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently increased by 1.38%, indicating that investor sentiment is decreasing. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldPro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthPro Medicus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Pro Medicus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 366.6, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently increased by 1.38%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Pro Medicus this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pro Medicus insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.84% of the stock of Pro Medicus is held by institutions.Read more about Pro Medicus' insider trading history. Receive PMCUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCUF Stock News HeadlinesUp 129% in a year, are Pro Medicus shares a buy ahead of tomorrow's FY 2025 results?August 12 at 10:04 PM | msn.comPro Medicus Partners with 4DMedical for Software DevelopmentJuly 31, 2025 | tipranks.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 13 at 2:00 AM | Crypto 101 Media (Ad)MA Financial Group Remains a Hold on Pro Medicus Limited (PMCUF)July 25, 2025 | theglobeandmail.comMorgans Keeps Their Sell Rating on Pro Medicus Limited (PMCUF)July 24, 2025 | theglobeandmail.comBell Potter downgrades Pro Medicus Limited (PMCUF) to a HoldJuly 24, 2025 | theglobeandmail.comOrd Minnett Reaffirms Their Hold Rating on Pro Medicus Limited (PMCUF)July 24, 2025 | theglobeandmail.comPro Medicus Ltd. (PMCUF) Stock Price Today - WSJJuly 3, 2025 | wsj.comSee More Headlines PMCUF Stock Analysis - Frequently Asked Questions How have PMCUF shares performed this year? Pro Medicus' stock was trading at $155.27 at the beginning of the year. Since then, PMCUF stock has increased by 24.9% and is now trading at $194.00. How do I buy shares of Pro Medicus? Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/13/2025Next Earnings (Estimated)8/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:PMCUF CIK2013003 Webwww.promed.com.au Phone61 3 9429 8800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio12,933.33 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:PMCUF) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro Medicus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.